Last reviewed · How we verify
MMX mesalamine/ mesalazine
MMX mesalamine is an anti-inflammatory agent that reduces inflammation in the colon by inhibiting prostaglandin and leukotriene production.
MMX mesalamine is a delayed-release formulation of the anti-inflammatory agent mesalamine that targets the colon to reduce inflammation in inflammatory bowel disease. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (induction and maintenance of remission).
At a glance
| Generic name | MMX mesalamine/ mesalazine |
|---|---|
| Also known as | Lialda, Mezavant, Mezavant XL, Mezavant LP |
| Sponsor | Shire |
| Drug class | 5-aminosalicylic acid (5-ASA) agent |
| Target | Prostaglandin and leukotriene synthesis; non-selective anti-inflammatory mechanism |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Mesalamine (5-aminosalicylic acid) acts as a topical anti-inflammatory in the gastrointestinal tract, primarily by inhibiting nuclear factor-kappa B (NF-κB) and reducing production of inflammatory mediators. The MMX formulation uses a multimatrix delivery system that delays drug release until the colon, allowing targeted delivery to the site of inflammation in inflammatory bowel disease.
Approved indications
- Ulcerative colitis (induction and maintenance of remission)
- Crohn's disease (colonic involvement)
Common side effects
- Headache
- Abdominal pain
- Diarrhea
- Nausea
- Nasopharyngitis
- Rash
Key clinical trials
- Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine (PHASE1)
- Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis (PHASE1)
- Prevention of Recurrence of Diverticulitis (PHASE3)
- Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis (PHASE3)
- Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) (PHASE4)
- Prevention of Recurrence of Diverticulitis (PHASE3)
- Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine (PHASE1)
- Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMX mesalamine/ mesalazine CI brief — competitive landscape report
- MMX mesalamine/ mesalazine updates RSS · CI watch RSS
- Shire portfolio CI